Vivani Medical (VANI)
NASDAQ:VANI
Want to see VANI full AI Analyst Report?
Top Page
Vivani Medical
(NASDAQ:VANI)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.50
▲(17.19% Upside)
Action:Reiterated
Date:05/14/26
Overall score is weighed down primarily by weak financial performance (no revenue, sizable ongoing losses, and heavy cash burn with increased leverage). Technical indicators add further pressure with price below key moving averages and negative MACD. Corporate updates and stated liquidity runway provide some offset, but do not outweigh the current pre-commercial risk profile.
Positive Factors
Advancing SLIM-1 trial
Executing a Phase 1 semaglutide implant trial is a durable de-risking milestone: positive Phase 1 data can validate Vivani's delivery technology, create a clear regulatory pathway, and materially increase partner or investor interest ahead of a planned Phase 2 dose-ranging program in 2027.
Negative Factors
Pre-revenue operations
Operating with no revenue means Vivani is entirely dependent on external financing and clinical success; persistent pre-revenue status amplifies dilution risk and makes the firm's long-term viability contingent on successful trials and subsequent commercial execution rather than organic cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Advancing SLIM-1 trial
Executing a Phase 1 semaglutide implant trial is a durable de-risking milestone: positive Phase 1 data can validate Vivani's delivery technology, create a clear regulatory pathway, and materially increase partner or investor interest ahead of a planned Phase 2 dose-ranging program in 2027.
Read all positive factors
Vivani Medical (VANI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$110.38M
Dividend YieldN/A
Average Volume (3M)216.92K
Price to Earnings (P/E)―
Beta (1Y)1.30
Revenue GrowthN/A
EPS Growth3.54%
CountryUS
Employees37
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.40
Shares Outstanding86,235,110
10 Day Avg. Volume237,036
30 Day Avg. Volume216,922
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.88
Price to Sales (P/S)0.00
P/FCF Ratio-3.01
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-588.53
Enterprise Value/Ebitda-2.80
Forecast
1Y Price Target
$3.75Price Target Upside192.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.33
Revenue Forecast (FY)N/A
Vivani Medical Business Overview & Revenue Model
Company Description
Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and...
How the Company Makes Money
null...
Vivani Medical Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
34
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -130.00K | -424.00K | 0.00 | -357.00K | 0.00 | 0.00 |
| EBITDA | -27.36M | -27.13M | -24.28M | -25.30M | -19.16M | -12.98M |
| Net Income | -27.09M | -26.61M | -23.49M | -25.65M | -13.89M | -12.77M |
Balance Sheet | ||||||
| Total Assets | 42.35M | 39.39M | 41.56M | 45.80M | 51.13M | 5.45M |
| Cash, Cash Equivalents and Short-Term Investments | 19.75M | 16.23M | 18.35M | 20.65M | 45.08M | 2.18M |
| Total Debt | 18.27M | 18.86M | 19.31M | 20.70M | 955.00K | 1.81M |
| Total Liabilities | 23.27M | 23.66M | 23.95M | 25.04M | 6.82M | 2.99M |
| Stockholders Equity | 19.09M | 15.73M | 17.61M | 20.76M | 44.31M | 2.46M |
Cash Flow | ||||||
| Free Cash Flow | -26.52M | -25.49M | -21.34M | -24.59M | -19.13M | -11.52M |
| Operating Cash Flow | -25.35M | -24.32M | -20.79M | -23.70M | -18.79M | -10.95M |
| Investing Cash Flow | -1.17M | -1.17M | -556.00K | -887.00K | -338.00K | -572.00K |
| Financing Cash Flow | 33.16M | 23.27M | 19.05M | 133.00K | 63.39M | 11.62M |
Vivani Medical Technical Analysis
Negative
1.28
Price Trends
1.21
Negative
1.24
Negative
1.31
Negative
Market Momentum
<0.01
Negative
43.39
Neutral
50.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VANI, the sentiment is Negative. The current price of 1.28 is above the 20-day moving average (MA) of 1.22, above the 50-day MA of 1.21, and below the 200-day MA of 1.31, indicating a bearish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 43.39 is Neutral, neither overbought nor oversold. The STOCH value of 50.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VANI.
Vivani Medical Risk Analysis
Vivani Medical disclosed 65 risk factors in its most recent earnings report. Vivani Medical reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vivani Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $119.88M | 17.60 | 3.81% | ― | 2.25% | -19.05% | |
56 Neutral | $64.53M | 34.91 | 3.68% | ― | -0.32% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $14.65M | -0.68 | -211.73% | ― | 8.92% | 17.49% | |
44 Neutral | $110.38M | -3.54 | -264.04% | ― | ― | 3.54% | |
44 Neutral | $43.33M | -1.73 | -81.52% | ― | 54.38% | 7.25% |
* Healthcare Sector Average
VANI
Vivani Medical
1.18
0.03
2.61%
FONR
Fonar
19.09
4.61
31.79%
NSPR
InspireMD
0.88
-1.62
-64.80%
XTNT
Xtant Medical Holdings
0.46
-0.24
-34.53%
ICCM
Icecure Medical
4.37
-25.51
-85.39%
Vivani Medical Corporate Events
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Vivani Highlights Q1 Progress on Semaglutide Implant Program
Positive
May 13, 2026
On May 13, 2026, Vivani Medical reported first-quarter 2026 results, highlighting progress toward launching SLIM-1, a Phase 1 trial of its NPM-139 semaglutide implant for chronic weight management in Australia, expected to begin mid-2026 with top-...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.